Kazia Therapeutics Limited (KZIA) Research

Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that can penetrate the brain and works by inhibiting the PI3K/Akt/mTor pathway, showing promise as a potential remedy for glioblastoma. The company is also progressing with EVT801, an experimental medication being investigated for its efficacy against various cancer types. Incorporated in 1994, the entity operated under the name Novogen Limited until its rebranding to Kazia Therapeutics Limited in November 2017. The company's main operations are based in Sydney, Australia.

Market snapshot

Symbol
KZIA
Price
$13.86
Day change
-2.74%
Market cap
$32.0M
P/E ratio
-2.77x
52-week range
4.86-17.4
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months
Analyst price target
$28.50

Peer companies

  • Biodexa Pharmaceuticals Plc (BDRX)
  • Can-Fite BioPharma Ltd. (CANF)
  • Clearmind Medicine Inc. (CMND)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • GRI Bio, Inc. (GRI)
  • InMed Pharmaceuticals Inc. (INM)
  • Oragenics, Inc. (OGEN)
  • Silo Pharma, Inc. (SILO)

Recent insider activity

  • Levine James E. — trade (0 shares) on 2026-06-01
  • Davidson Ebru — trade (2000 shares) on 2026-03-18
  • Davidson Ebru — trade (75000 shares) on 2026-03-18
  • Rao Sudha — trade (0 shares) on 2026-04-13
  • Friend John E. II — trade (30000 shares) on 2026-03-18

Open Kazia Therapeutics Limited (KZIA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.